Efficacy of Adjunctive Therapies for Acute Ischemic Stroke Based on Phase 3 MOST Trial скачать в хорошем качестве

Efficacy of Adjunctive Therapies for Acute Ischemic Stroke Based on Phase 3 MOST Trial

In a recent analysis of the phase 3, randomized controlled MOST trial (NCT03735979) assessing argatroban or eptifibatide, findings showed that both treatments failed efficacy in reducing disability in patients with AIS treated with thrombolysis within 3 hours of symptom onset. The findings were presented at the 2024 International Stroke Conference (ISC), held February 7-9, in Phoenix, Arizona, by lead author Opeolu Adeoye, MD, MS, professor of emergency medicine at the Washington University in St. Louis, and senior author Andrew Barerrto, MD, MS, associate professor of neurosurgery, McGovern Medical School at UTHealth Houston. During the meeting, the duo sat down with NeurologyLive® in an interview to provide an overview of the methods of the trial and further discuss the findings. Click to read more: https://www.neurologylive.com/view/ef... More ISC Content: https://www.neurologylive.com/confere...